Aurobindo Pharma Limited (AUROPHARMA) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE406A01037
Key metrics
- Market Cap
- ₹94,834 Cr
- P/E Ratio
- 25.77
- EPS
- 63.97
- Book Value
- 652.25
- P/B Ratio
- 2.57
- ROE
- 9.25%
- ROCE
- 11.3%
- Debt / Equity
- 0.21
- Net Margin
- 10.5%
- Revenue Growth
- 6.39%
- Profit Growth
- 0.54%
- Dividend Yield
- 0.24%
- 52W High
- ₹1,717.00
- 52W Low
- ₹1,021.00
- Market Cap Band
- large cap
- Face Value
- 1
Ratios computed from the annual results period ending 2026-03-31.
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
- Headquarters
- Hyderabad, India
- Employees
- 29,209
- Promoter Holding
- 54.78%
The full Aurobindo Pharma Limited analysis
Create a free account to open the complete AUROPHARMA deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.